title: Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes: therapeutic strategy for herpetic stromal keratitis.
abstract: Ocular neovascularization often results in vision impairment. Frequently vascular endothelial cell growth factors (VEGFs) are mainly responsible for the pathological neovascularization as in the case in neovascularization induced by CpG oligodeoxynucleotides and herpes simplex virus infection in this report. siRNAs targeting either VEGFA, VEGFR1, VEGFR2, or a mix of the three were shown to significantly inhibit neovascularization induced by CpG when given locally or systemically. The efficacy of systemic administration was facilitated by the use of a polymer delivery vehicle. Additional experiments showed a significant inhibitory effect of the siRNAs mix when given either locally or systemically in vehicle against herpes simplex virus-induced angiogenesis as well as against lesions of stromal keratitis. These results indicate that the use of VEGF pathway-specific siRNAs represents a useful therapy against neovascularization-related eye diseases.
authors.affiliation: Comparative and Experimental Medicine, College of Veterinary Medicine, University of Tennessee, Knoxville, TN 37996-0845, USA.
authors.forename: Bumseok
authors.initials: B
authors.lastname: Kim
authors.forename: Qingquan
authors.initials: Q
authors.lastname: Tang
authors.forename: Partha S
authors.initials: PS
authors.lastname: Biswas
authors.forename: Jun
authors.initials: J
authors.lastname: Xu
authors.forename: Raymond M
authors.initials: RM
authors.lastname: Schiffelers
authors.forename: Frank Y
authors.initials: FY
authors.lastname: Xie
authors.forename: Aslam M
authors.initials: AM
authors.lastname: Ansari
authors.forename: Puthupparampil V
authors.initials: PV
authors.lastname: Scaria
authors.forename: Martin C
authors.initials: MC
authors.lastname: Woodle
authors.forename: Patrick
authors.initials: P
authors.lastname: Lu
authors.forename: Barry T
authors.initials: BT
authors.lastname: Rouse
mesh_terms: D000818:Animals; D016510:Corneal Neovascularization / Q000209:etiology* / Q000517:prevention & control; D019573:Epithelium, Corneal / Q000378:metabolism / Q000821:virology; D005260:Female; D006561:Herpes Simplex / Q000150:complications / Q000188:drug therapy / Q000821:virology; D016849:Keratitis, Herpetic / Q000150:complications* / Q000188:drug therapy / Q000821:virology; D051379:Mice; D008807:Mice, Inbred BALB C; D009838:Oligodeoxyribonucleotides / Q000008:administration & dosage; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D034741:RNA, Small Interfering / Q000494:pharmacology*; D015398:Signal Transduction; D018139:Simplexvirus / Q000302:isolation & purification; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D040281:Vascular Endothelial Growth Factor Receptor-1 / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism
chemical_list: C408982:CPG-oligonucleotide; D009838:Oligodeoxyribonucleotides; D012333:RNA, Messenger; D034741:RNA, Small Interfering; D042461:Vascular Endothelial Growth Factor A; D040281:Vascular Endothelial Growth Factor Receptor-1; D040301:Vascular Endothelial Growth Factor Receptor-2